Although recombinant
glucocerebrosidase (GCase) is the standard
therapy for the inherited
lysosomal storage disease Gaucher's disease (GD),
enzyme replacement is not effective when the central nervous system is affected. We created a series of recombinant genes/
proteins where GCase was linked to different membrane binding
peptides including the Tat
peptide, the
rabies glycoprotein derived
peptide (RDP), the binding domain from
tetanus toxin (TTC), and a
tetanus like
peptide (Tet1). The majority of these
proteins were well-expressed in a mammalian producer cell line (HEK 293F). Purified recombinant Tat-GCase and RDP-GCase showed similar GCase
protein delivery to a neuronal cell line that genetically lacks the functional
enzyme, and greater delivery than control GCase,
Cerezyme (Genzyme). This initial result was unexpected based on observations of superior
protein delivery to neurons with RDP as a vector. A
recombinant protein where a fragment of the flexible hinge region from
IgA (IgAh) was introduced between RDP and GCase showed substantially enhanced GCase neuronal delivery (2.5 times over Tat-GCase), suggesting that the original construct resulted in interference with the capacity of RDP to bind neuronal membranes. Extended treatment of these knockout neuronal cells with either Tat-GCase or RDP-IgAh-GCase resulted in an >90% reduction in the
lipid substrate
glucosylsphingosine, approaching normal levels. Further in vivo studies of RDP-IgAh-GCase as well as Tat-GCase are warranted to assess their potential as treatments for neuronopathic forms of GD. These
peptide vectors are especially attractive as they have the potential to carry a
protein across the blood-brain barrier, avoiding invasive direct brain delivery.